Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$6.31M-12.60%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael T. Nally
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 312
- Beta
- -0.14
- Country
- US
Financials
GENB has only 2 quarterly periods on file — the charts below show the full history available.
Revenue
$6.31M-12.6%Net Income
$-67.25MEBITDA
$-63.82MFree Cash Flow
$-58.88MEPS (diluted)
$-0.52Shares Outstanding (diluted)
128.24M+0.0%Operating Expenses
$77.93MCash & Debt
$457.42MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $31.89M | $-203.15M | $-4.98 |
| 2024 | $20.46M | $-173.77M | $-1.68 |
Valuation
GENBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
140+366.67%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·21h ago·Negative
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases Collaboration will combine Zealand Pharma's expertise in metabolic health with Generate's proprietary generative AI platform to create multispecific drug candidates with tailored biological functions
View source ↗ - Newsseekingalpha.com·1d ago·Positive
…he Algorithm Generate Biomedicines offers a compelling long-acting asthma biologic, golukibart (GB-0895), targeting twice-yearly dosing and broad phenotype efficacy. GENB leads the TSLP antagonist race with two global Phase 3 trials underway, aiming to displace Tezspire and capitalize on significant asthma and COPD market upside. Cash runway extends into early 2028, but Phase 3 trial costs and potential dilution before topline data are key risks to monitor.
View source ↗ - Newsglobenewswire.com·36d ago·Neutral
Generate Biomedicines Inc. to Participate in September Investor Conferences SOMERVILLE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (Nasdaq: GENB) (“Generate”) today announced that members of its management team will participate in presentations at the following investor conferences:
View source ↗ - Newsproactiveinvestors.com·50d ago·Negative
Generate Biomedicines stock jumps as post-IPO lock-up set to expire Shares of Generate Biomedicines Inc (NASDAQ:GENB) jumped more than 20% on Tuesday as investors positioned ahead of the expiration of the company's post-IPO lock-up period. The lock-up, which ends Wednesday, will free company insiders, early investors and major shareholders to sell shares issued as part of Generate's $400 million initial public offering earlier this year, which included 25 million shares.
View source ↗
Earnings
Thu, Nov 5(in 3 weeks)
Consensus estimate $-0.51 per share
Typical surprise -2.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.52 vs $-0.51miss
Estimates and results for GENB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in GENB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.